Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
about
Molecular heterogeneity in glioblastoma: potential clinical implicationsTemozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 ExpressionSmall molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cellsMetabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with TemozolomideFunctional role of DNA mismatch repair gene PMS2 in prostate cancer cells.Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomideIntratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.Filamin C promotes lymphatic invasion and lymphatic metastasis and increases cell motility by regulating Rho GTPase in esophageal squamous cell carcinomaAcquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.A comprehensive profile of recurrent glioblastoma.The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.The Process and Regulatory Components of Inflammation in Brain Oncogenesis.Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.ATP7B expression confers multidrug resistance through drug sequestrationEndoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51ATP7B expression in human glioblastoma is related to temozolomide resistance.
P2860
Q28088605-A2E79603-B73E-4D72-9AED-1A90B0F8E330Q28550138-6B679B88-7EC4-4699-A4EA-5FBB74D1526CQ33798642-7A407ACB-8E7F-48CD-BF7B-061F9E5C8A29Q34318242-3FD35132-5D5A-44BA-85B9-DFB74542AA8AQ34478988-E61CCF3D-2F4E-46B4-A54E-CE93DECD75B6Q34786598-00EEDC12-7C80-48FA-AD02-3491C0B53EC5Q36650859-036B5AEF-A909-4EBA-8C51-E9AA1B1211F9Q37701605-CC628AE6-3282-473A-8295-F216853E17BAQ38694505-2DA11655-CD11-4E75-8298-A1BF89C340DDQ38797345-F9055FAB-EFE2-4271-95C3-0E499D3648C8Q38819651-7EA2B624-2560-4CC7-9E14-802551D8B28CQ38907925-E127F410-C937-4BBB-8822-F9314BD6833BQ38940136-532E52A8-4859-42F9-9679-EE6B9892CDE0Q39202332-6F894365-643D-43E3-976D-3D4A48A1EE54Q40720470-DB5FBD3A-95C9-4990-8B98-16C466DF347AQ40997062-FAB71288-043C-4732-91C6-C2A3E5B2B049Q42014579-DA554A0F-7BBF-482E-9214-312EDC0DB01DQ47130958-8961EEAD-BE74-48D4-8C76-9FE3A71B2292
P2860
Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Reduction of MLH1 and PMS2 con ...... th recurrence of glioblastoma.
@en
Reduction of MLH1 and PMS2 con ...... th recurrence of glioblastoma.
@nl
type
label
Reduction of MLH1 and PMS2 con ...... th recurrence of glioblastoma.
@en
Reduction of MLH1 and PMS2 con ...... th recurrence of glioblastoma.
@nl
prefLabel
Reduction of MLH1 and PMS2 con ...... th recurrence of glioblastoma.
@en
Reduction of MLH1 and PMS2 con ...... th recurrence of glioblastoma.
@nl
P2093
P2860
P356
P1433
P1476
Reduction of MLH1 and PMS2 con ...... th recurrence of glioblastoma.
@en
P2093
Hajime Yonezawa
Hirofumi Hirano
Hiroshi Tokimura
Kazunori Arita
Kentarou Minami
Kohichi Kawahara
Masatatsu Yamamoto
Ryuji Ikeda
Shunji Yunoue
Tatsuhiko Furukawa
P2860
P304
P356
10.18632/ONCOTARGET.1302
P407
P577
2013-12-01T00:00:00Z